Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC
← catalyst calendarNCT05374603 · readout in 152 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
47actual
Sites
16
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-11-15 | actual | When the study began enrolling |
| Primary completion | 2027-01-18 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-01-18 | estimated | The whole study's end, after follow-up |
| First posted | 2022-05-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Lung Cancer
Interventions
- Drug: Savolitinib
- Drug: Durvalumab
Primary outcome
what the primary-completion date above is the date OFPFS
measured The analysis will occur when 60 percent PFS event is observed in each cohort, at approximately 10 months after last patient in.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed